DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Google Secures Pentagon AI Deal for Classified Projects 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
KING OF PRUSSIA, Pa., April 26, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the 42nd Annual Healthcare Conference hosted by Deutsche Bank Securities on Wednesday, May 3, 2017, at 2:50 p.m. EDT in Boston.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection), currently in Phase 3 development for the management of moderate-to-severe acute pain. Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
